A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im et al. · The Lancet Oncology · 2011 · 2.4K citations

Medicine, Oncology, Pharmacology +16

Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

W. Fraser Symmans, Florentia Peintinger, Christos Hatzis et al. · Journal of Clinical Oncology · 2007 · 1.7K citations · Full text

Medicine, Oncology, Breast Oncology +16

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

Stephen Chia, Tamas Hickish, V. Harvey et al. · Annals of Oncology · 2013 · 1.3K citations

Medicine, Oncology, Pharmacology +14

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Luca Gianni, W. Eiermann, Alexey Manikhas et al. · The Lancet · 2010 · 1.3K citations

Medicine, Oncology, Breast Oncology +16

Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

Purva Bali, Michael Pranpat, James E. Bradner et al. · Journal of Biological Chemistry · 2005 · 749 citations · Full text

Life Sciences, Molecular Biology, Oncology +17